| Business Summary | | Regeneron
Pharmaceuticals
is
a
biopharmaceutical
company
that
discovers,
develops,
and
intends
to
commercialize
therapeutic
drugs
for
the
treatment
of
serious
medical
conditions.
Expanding
from
its
initial
focus
on
degenerative
neurologic
diseases,
the
Company
has
more
recently
broadened
its
product
pipeline
to
include
drug
candidates
for
the
treatment
of
obesity,
rheumatoid
arthritis,
cancer,
allergies,
asthma,
ischemia,
and
other
diseases
and
disorders. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | REGN
is
a
biopharmaceutical
company
that
discovers,
develops,
and
intends
to
commercialize
therapeutic
drugs
for
the
treatment
of
serious
medical
conditions.
For
the
six
months
ended
6/30/01,
total
revenues
fell
52%
to
$12.1
million.
Net
loss
before
acct.
change
rose
from
$10.1
million
to
$27.9
million.
Revenues
reflect
lower
research
payments
on
the
Proctor
and
Gamble
contract.
Higher
loss
reflects
staff
additions,
and
increased
preclinical
and
clinical
research
activities. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| P. Roy Vagelos, M.D., 71 Chairman | -- | -- | Leonard Schleifer, M.D., Ph.D., 48 Pres,
CEO, Director | $596K | -- | Murray Goldberg, 56 CFO,
Sr. VP-Fin. and Admin.,Treasurer, Assistant Secre | 260K | $863K | George Yancopoulos, M.D., Ph.D., 41 Exec.
VP, CSO and Pres, Regeneron Research Laboratories, | 374K | -- | Randall Rupp, Ph.D., 53 Sr.
VP, Manufacturing and Process Sciences | 229K | 101K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|